The turnover of Biotechnology Research and Experimental Development in Sweden has experienced significant growth from 2013 through 2023. Starting at 121.0 million Euros in 2013, it has reached 260.9 million Euros in 2023, marking an impressive 115.6% increase over this period. Notable fluctuations include a steep rise of 27.98% in 2016 and 35.15% in 2019. The last five years saw consistent growth with a 4.49% year-on-year increase in 2023 and a 10.61% CAGR.
Future projections indicate a continued upward trend, with turnover forecasted to reach 316.1 million Euros by 2028. Over this upcoming period, growth is expected to slow slightly, with a 5-year forecasted CAGR of 3.05%. The Biotechnology sector in Sweden remains robust, backed by ongoing investment in R&D and an increasing focus on innovation.
Trends to watch include:
- Technological advancements in biotechnology, enhancing research capabilities.
- Government policies and funding strategies supporting biotech initiatives.
- Expansion into new therapeutic areas and commercial applications.
- Potential impacts of global economic conditions on research funding and investments.
